An update on the strategies in multicomponent activity monitoring within the phytopharmaceutical field

BMC Complementary and Alternative Medicine

Florian Ueberall¹  Dietmar Fuchs²  Marcel Jenny¹  Oliver A Wrulich¹  Johanna M Gostner¹ 

[1] Division of Medical Biochemistry, Biocenter, Innsbruck Medical University, Fritz-Pregl-Str. 3, 6020 Innsbruck, Austria;Division of Biological Chemistry, Biocenter, Innsbruck Medical University, Fritz-Pregl-Str. 3, 6020 Innsbruck, Austria

关键词: Network;    Microarray;    Effect potentialization;    Multitarget;    Multicomponent;   

Others  :  1232834
DOI  :  10.1186/1472-6882-12-18

 received in 2011-09-22, accepted in 2012-03-14,  发布年份 2012

【 摘 要 】

Background

To-date modern drug research has focused on the discovery and synthesis of single active substances. However, multicomponent preparations are gaining increasing importance in the phytopharmaceutical field by demonstrating beneficial properties with respect to efficacy and toxicity.

Discussion

In contrast to single drug combinations, a botanical multicomponent therapeutic possesses a complex repertoire of chemicals that belong to a variety of substance classes. This may explain the frequently observed pleiotropic bioactivity spectra of these compounds, which may also suggest that they possess novel therapeutic opportunities. Interestingly, considerable bioactivity properties are exhibited not only by remedies that contain high doses of phytochemicals with prominent pharmaceutical efficacy, but also preparations that lack a sole active principle component. Despite that each individual substance within these multicomponents has a low molar fraction, the therapeutic activity of these substances is established via a potentialization of their effects through combined and simultaneous attacks on multiple molecular targets. Although beneficial properties may emerge from such a broad range of perturbations on cellular machinery, validation and/or prediction of their activity profiles is accompanied with a variety of difficulties in generic risk-benefit assessments. Thus, it is recommended that a comprehensive strategy is implemented to cover the entirety of multicomponent-multitarget effects, so as to address the limitations of conventional approaches.

Summary

An integration of standard toxicological methods with selected pathway-focused bioassays and unbiased data acquisition strategies (such as gene expression analysis) would be advantageous in building an interaction network model to consider all of the effects, whether they were intended or adverse reactions.

【 授权许可】

   
2012 Gostner et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Newman DJ, Cragg GM: Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007, 70:461-477.
• [2]Schmidt B, Ribnicky DM, Poulev A, Logendra S, Cefalu WT, Raskin I: A natural history of botanical therapeutics. Metabolism 2008, 57(Suppl 1):S3-S9.
• [3]Schmidt BM, Ribnicky DM, Lipsky PE, Raskin I: Revisiting the ancient concept of botanical therapeutics. Nat Chem Biol 2007, 3:360-366.
• [4]Hopkins AL, Mason JS, Overington JP: Can we rationally design promiscuous drugs? Curr Opin Struct Biol 2006, 16:127-136.
• [5]Hopkins AL: Network pharmacology. Nat Biotechnol 2007, 25:1110-1111.
• [6]Roth BL, Sheffler DJ, Kroeze WK: Magic shotguns versus magic bullets: selectively nonselective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004, 3:353-359.
• [7]Van-Vuuren S, Viljoen A: Plant-based antimicrobial studies-methods and approaches to study the interaction between natural products. Planta Med 2011, 77:1168-1182.
• [8]Rasoanaivo P, Wright CW, Willcox ML, Gilbert B: Whole plant extracts versus single compounds for the treatment of malaria: synergy and positive interactions. Malar J 2011, 15(Suppl 1):S4.
• [9]Borisy AA, Elliott PJ, Hurst NW, Lee MS, Lehar J, Price ER, Serbedzija G, Zimmermann GR, Foley MA, Stockwell BR, Keith CT: Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci USA 2003, 100:7977-7982.
• [10]Veit M: Trockenextrakte als Arzneistoff: Herstellung, Qualitätsprüfung. In Pharmakognosie Phytopharmazie. Edited by Haensel R, Sticher O. Heidelberg, Springer Medizin Verlag; 2010:218-246.
• [11]NIH Office of Dietary Supplements: National Institutes of Health- Office of Dietary Supplements. [http://ods.od.nih.gov/factsheets/BotanicalBackground/] webcite 2011.
• [12]Kalra EK: Nutraceutical-definition and introduction. AAPS PharmSci 2003, 5:E25.
• [13]Groten JP, Butler W, Feron VJ, Kozianowski G, Renwick AG, Walker R: An analysis of the possibility for health implications of joint actions and interactions between food additives. Regul Toxicol Pharmacol 2000, 31:77-91.
• [14]Wagner H, Ulrich-Merzenich G: Synergy research: approaching a new generation of phytopharmaceuticals. Phytomedicine 2009, 16:97-110.
• [15]Keith CT, Borisy AA, Stockwell BR: Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 2005, 4:71-78.
• [16]Kaput J: Nutrigenomics research for personalized nutrition and medicine. Curr Opin Biotechnol 2008, 19:110-120.
• [17]Panagiotou G, Nielsen J: Nutritional systems biology: definitions and approaches. Annu Rev Nutr 2009, 29:329-339.
• [18]Waters M, Jackson M: Databases applicable to quantitative hazard/risk assessment- towards a predictive systems toxicology. Toxicol Appl Pharmacol 2008, 233:34-44.
• [19]Zhong S, Romkes M: Pharmacogenomics Methods Mol Biol. 2009, 520:231-245.
• [20]Scalbert A, Andres-Lacueva C, Arita M, Kroon P, Manach C, Urpi-Sarda M, Wishart D: Databases on food phytochemicals and their health-promoting effects. J Agric Food Chem 2011, 59:4331-4348.
• [21]Schäfer H, Wink M: Medicinally important secondary metabolites in recombinant microorganisms or plants: progress in alkaloid biosynthesis. Biotechnol J 2009, 4:1684-1703.
• [22]Wink M: Evolutionary advantage and molecular modes of action of multi-component mixtures used in phytomedicine. Curr Drug Metab 2008, 9:996-1009.
• [23]Csermely P, Agoston V, Pongor S: The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 2005, 26:178-182.
• [24]Cassee FR, Groten JP, Van-Bladeren PJ, Feron VJ: Toxicological evaluation and risk assessment of chemical mixtures. Crit Rev Toxicol 1998, 28:73-101.
• [25]Berenbaum MC: What is synergy? Pharmacol Rev 1989, 41:93-141.
• [26]Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
• [27]Lila MA, Raskin I: Health-related Interactions of Phytochemicals. JFS 2005, 70:20-27.
• [28]Stierum R, Heijne W, Kienhuis A, Van-Ommen B, Groten J: Toxicogenomics concepts and applications to study hepatic effects of food additives and chemicals. Toxicol Appl Pharmacol 2005, 207(2 Suppl):179-188.
• [29]Kitano H: A robustness-based approach to systems-oriented drug design. Nat Rev Drug Discov 2007, 6:202-210.
• [30]Libby P, Theroux P: Pathophysiology of coronary artery disease. Circulation 2005, 111:3481-3488.
• [31]Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
• [32]Ramsey SA, Gold ES, Aderem A: A systems biology approach to understanding atherosclerosis. EMBO Mol Med 2010, 2:79-89.
• [33]Pittler MH, Ernst E: Complementary therapies for peripheral arterial disease: systematic review. Atherosclerosis 2005, 181:1-7.
• [34]McKenna DJ, Ruiz JM, Hoye TR, Roth BL, Shoemaker AT: Receptor screening technologies in the evaluation of Amazonian ethnomedicines with potential applications to cognitive deficits. J Ethnopharmacol 2011, 134:475-492.
• [35]Elisabetsky E: Phytotherapy and the new paradigm of drugs mode of action. Revista Productos Naturales 2007, 12:459-464.
• [36]Wirleitner B, Neurauter G, Schröcksnadel K, Frick B, Fuchs D: Interferon-gammainduced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr Med Chem 2003, 10:1581-1591.
• [37]Ulrich-Merzenich G, Zeitler H, Jobst D, Panek D, Vetter H, Wagner H: Application of the "-Omic-" technologies in phytomedicine. Phytomedicine 2007, 14:70-82.
• [38]Williamson EM: Synergy and other interactions in phytomedicines. Phytomedicine 2001, 8:401-409.
• [39]Balászi G, Oltvai ZN: Sensing your surroundings: how transcription-regulatory networks of the cell discern environmental signals. Sci STKE 2005, 282:20.
• [40]Kitano H: Biological robustness. Nat Rev Genet 2004, 5:826-837.
• [41]Barkai N, Leibler S: Robustness in simple biochemical networks. Nature 1997, 387:913-917.
• [42]Lehár J, Krueger A, Zimmermann G, Borisy A: High-order combination effects and biological robustness. Mol Syst Biol 2008, 4:1-6.
• [43]Zimmermann GR, Lehár J, Keith CT: Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 2007, 12:34-42.
• [44]Spurgeon DJ, Jones OA, Dorne JL, Svendsen C, Swain S, Stürzenbaum SR: Systems toxicology approaches for understanding the joint effects of environmental chemical mixtures. Sci Total Environ 2010, 408:3725-3734.
• [45]New DC, Miller-Martini DM, Wong YH: Reporter gene assays and their applications to bioassays of natural products. Phytother Res 2003, 17:439-448.
• [46]Olden K: Toxicogenomics-a new systems toxicology approach to understanding of gene-environment interactions. Ann N Y Acad Sci 2006, 1076:703-706.
• [47]Qiu YQ, Zhang S, Zhang XS, Chen L: Detecting disease associated modules and prioritizing active genes based on high throughput data. BMC Bioinformatics 2010, 11:26. BioMed Central Full Text
• [48]Hopkins AL: Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008, 4:682-690.
• [49]Agoston V, Csermely P, Pongor S: Multiple weak hits confuse complex systems: a transcriptional regulatory network as an example. Phys Rev E Stat Nonlin Soft Matter Phys 2005, 71:051909.
• [50]Alon U: Network motifs: theory and experimental approaches. Nat Rev Genet 2007, 8:450-461.
• [51]Banerjee N, Zhang MQ: Functional genomics as applied to mapping transcription regulatory networks. Curr Opin Microbiol 2002, 5:313-317.
• [52]Alon U: Simplicity in biology. Nature 2007, 446:497.
• [53]Mahadevan B: Omics: Tools for studying and understanding systems toxicology. Mutat Res 2010, 705:163-164.
• [54]Pearson K: On Lines and Planes of Closest Fit to Systems of Points in Space. Philosophical Magazine 1901, 2:559-572.
• [55]Ringnér M: What is principal component analysis? Nat Biotechnol 2008, 26:303-304.
• [56]Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998, 95:14863-14868.
• [57]Tavazoie S, Hughes JD, Campbell MJ, Cho RJ, Church GM: Systematic determination of genetic network architecture. Nat Genet 1999, 22:281-285.
• [58]Törönen P, Kolehmainen M, Wong G, Castrén E: Analysis of gene expression data using self-organizing maps. FEBS Lett 1999, 451:142-146.
• [59]Tamayo P, Slonim D, Mesirov J, Zhu Q, Kitareewan S, Dmitrovsky E, Lander ES, Golub TR: Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc Natl Acad Sci USA 1999, 96:2907-2912.
• [60]Getz G, Levine E, Domany E: Coupled two-way clustering analysis of gene microarray data. Proc Natl Acad Sci USA 2000, 97:12079-12084.
• [61]Gene Ontology Consortium: Gene Ontology Consortium, The Gene Ontology in 2010: extensions and refinements. Nucleic Acids Res 2009, 38:D331-D335.
• [62]Huang DW, Sherman BT, Lempicki RA: Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2008, 37:1-13.
• [63]Khatri P, Draghici S, Ostermeier GC, Krawetz SA: Profiling gene expression using onto-express. Genomics 2002, 79:266-270.
• [64]Berriz GF, King OD, Bryant B, Sander C, Roth FP: Characterizing gene sets with FuncAssociate. Bioinformatics 2003, 19:2502-2504.
• [65]Castillo-Davis CI, Hartl DL: GeneMerge-post-genomic analysis, data mining, and hypothesis testing. Bioinformatics 2003, 19:891-892.
• [66]Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA: DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003, 4:3. BioMed Central Full Text
• [67]Doniger SW, Salomonis N, Dahlquist KD, Vranizan K, Lawlor SC, Conklin BR: MAPPFinder: using Gene Ontology and GenMAPP to create a global gene-expression profile from microarray data. Genome Biol 2003, 4:R7. BioMed Central Full Text
• [68]Zeeberg BR, Feng W, Wang G, Wang MD, Fojo AT, Sunshine M, Narasimhan S, Kane DW, Reinhold WC, Lababidi S, Bussey KJ, Riss J, Barrett JC, Weinstein JN: GoMiner: a resource for biological interpretation of genomic and proteomic data. Genome Biol 2003, 4:28. BioMed Central Full Text
• [69]Hayles B, Yellaboina S, Wang D: Comparing transcription rate and mRNA abundance as parameters for biochemical pathway and network analysis. PLoS One 2010, 5:e9908.
• [70]Stark J, Callard R, Hubank M: From the top down: towards a predictive biology of signalling networks. Trends Biotechnol 2003, 21:290-293.
• [71]Werner T: Bioinformatics applications for pathway analysis of microarray data. Curr Opin Biotechnol 2008, 19:50-54.
• [72]Vera J, Wolkenhauer O: A system biology approach to understand functional activity of cell communication systems. Methods Cell Biol 2008, 90:399-415.
• [73]Pomati F, Orlandi C, Clerici M, Luciani F, Zuccato E: Effects and interactions in an nvironmentally relevant mixture of pharmaceuticals. Toxicol Sci 2008, 102:129-137.
• [74]Box GEP, Hunter WG, Hunter JS: Statistics for Experimenters: An Introduction to Design, Data Analysis and Model Building. New York: John Wiley & Sons; 2005.
• [75]Kauffman KJ, Ogunnaike BA, Edwards JS: Designing experiments that aid in the identification of regulatory networks. Brief Funct Genomic Proteomic 2006, 4:331-342.
• [76]Georgiou NA, Garssen J, Witkamp RF: Pharma-nutrition interface: the gap is narrowing. Eur J Pharmacol 2010, 651:1-8.
• [77]Yuliana ND, Khatib A, Choi YH, Verpoorte R: Metabolomics for bioactivity assessment of natural products. Phytother Res 2011, 25:157-169.